CAMBRIDGE, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today presented new data demonstrating for the first time the potential for redosing with an investigational, in vivo CRISPR/Cas9 genome editing therapy. These data from the ongoing Phase 1 study of NTLA-2001, a single-dose treatment in development for transthyretin (ATTR) amyloidosis, were presented at t ...

Presentation Details In the dose-escalation portion of the Phase 1 study, the initial three patients received the lowest dose of 0.1 mg/kg and subsequently received a follow-on dose of 55 mg. These data will be the first-ever clinical data from patients redosed with an in vivo CRISPR-based gene editing candidate and provide insight on the safety and pharmacodynamic effect. While repeat dosing is not planned for the NTLA-2001 program for ATTR amyloidosis, a redosing option could be an important advantage of ...

If the data from the MAGNITUDE study is found to be positive, it will enable global regulatory filings for NTLA-2001. Image Source: Zacks Investment Research This apart, NTLA submitted a clinical trial application to initiate a first-in-human phase I study of NTLA-3001 in December 2023. The company plans to begin patient dosing later in 2024. Some better-ranked stocks in the healthcare sector are Acrivon Therapeutics, Inc. (ACRV) and Aligos Therapeutics, Inc. (ALGS) , each carrying a Zacks Rank #2 (Buy) at ...

CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company's in vivo programs use CRISPR to enable precise editing of diseas ...

CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors. Mr. Goff joins the Intellia board of directors with over three decades of commercialization, operations and sales and marketing experience at leading biopharmaceutical companies. He is a seasoned and accomplished executive global lea ...

On June 2, Intellia Therapeutics' (NTLA -0.96%) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words that are sure to make at least a few savvy investors salivate. The stock briefly rose 8% above where it was before the announcement. This is a good omen Such patients might still technically have the disorder, as it is currently impossible for 100% of the copies of their genes, which are distributed across the my ...

Artur Plawgo Intellia Therapeutics (NASDAQ:NTLA) recently reported strong data from the Phase I portion of an ongoing Phase I/II study for NTLA-2002, an in vivo CRISPR-based gene editing therapy for hereditary angioedema (HAE). I have previously written about CRISPR Therapeutics (CRSP) and rated the company a strong buy due to its progress in the commercialization of Casgevy, an ex vivo CRISPR-based gene editing therapy. While CRISPR Therapeutics remains a strong buy, certain advantages of Intellia's therap ...

Intellia Therapeutics' (NTLA) shares gained 10% on Jun 3 after the company reported encouraging long-term data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema (HAE). Shares of NTLA continued to gain another 1.1% in the after-market hours. Image Source: Zacks Investment Research A total of 10 patients are being treated in the phase I portion of the study with either of the three one-time doses (25 mg, 50 mg, or 75 mg) of NTLA-2002,administered ...

From a technical perspective, Intellia Therapeutics, Inc. (NTLA) is looking like an interesting pick, as it just reached a key level of support. NTLA recently overtook the 50-day moving average, and this suggests a short-term bullish trend.The 50-day simple moving average is a widely used technical indicator that helps determine support or resistance levels for different types of securities. It's one of three major moving averages, but takes precedent because it's the first sign of an up or down trend.NTLA ...

财务表现 - Intellia Therapeutics, Inc. (NTLA)在2024年第一季度报告的每股亏损为1.06美元，比Zacks Consensus Estimate的每股亏损1.35美元窄[1]。 - 公司报告的亏损不包括一次性投资公平价值变动支出，包括这项支出在内，公司在2024年第一季度报告的每股亏损为1.12美元[2]。 - NTLA的总收入目前仅包括合作收入，2024年第一季度NTLA报告的收入为2,890万美元，而去年同期报告的收入为1,260万美元[3]。 - 公司的合作收入也超过了我们的模型估计的1,280万美元[4]。 - 研发支出总计1.118亿美元，比去年同期的数字增长了近15.1%[5]。 - 行政费用年同比增长约13.5%，达到3,110万美元，主要是由于股权补偿的增加[6]。 - 截至2024年3月31日，NTLA的现金、现金等价物和可市场出售证券价值为9.534亿美元，而截至2023年12月31日为10亿美元[7]。 合作与研发 - NTLA正在与Regeneron Pharmaceuticals (REGN)合作开发其研究中的体内基因编辑候选药NTLA-2001[8]。 - 公司计划在2024年下半年开始对NTLA-2002在HAE适应症中进行美国患者的关键第三阶段研究，取决于监管部门的反馈[9]。